Harvest Fund Management Co. Ltd Has $1.95 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Harvest Fund Management Co. Ltd raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 27.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,819 shares of the company's stock after acquiring an additional 1,028 shares during the period. Harvest Fund Management Co. Ltd's holdings in IDEXX Laboratories were worth $1,947,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Cranbrook Wealth Management LLC raised its holdings in IDEXX Laboratories by 7.0% in the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after acquiring an additional 25 shares during the period. Perigon Wealth Management LLC grew its position in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after purchasing an additional 26 shares during the last quarter. Summit Trail Advisors LLC increased its stake in shares of IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares during the period. First Horizon Advisors Inc. lifted its position in shares of IDEXX Laboratories by 4.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 704 shares of the company's stock worth $356,000 after purchasing an additional 27 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in IDEXX Laboratories by 4.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 743 shares of the company's stock valued at $375,000 after purchasing an additional 31 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective on the stock. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Piper Sandler lifted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, March 15th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Price Performance

NASDAQ:IDXX traded up $2.61 on Monday, reaching $423.60. The stock had a trading volume of 616,827 shares, compared to its average volume of 552,334. The company has a market capitalization of $34.34 billion, a P/E ratio of 39.70, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The stock has a fifty day moving average price of $437.36 and a 200-day moving average price of $444.76. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $548.88.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.